Bristol Myers Squibb’s Opdivo was recently granted FDA approval in combination with cisplatin and gemcitabine as a first-line treatment for metastatic urothelial carcinoma. With this approval, Opdivo positions itself to compete with Merck & Co’s immune checkpoint inhibitor Keytruda in combination with Astellas and Pfizer’s Padcev, a nectin-4-directed antibody-drug conjugate, according to GlobalData.
Tag Archive for: Astellas
Astellas is returning to the Super Bowl to help educate game viewers about VEOZAH and vasomotor symptoms (VMS), the most commonly reported menopause symptoms. The “Fewer Hot Flashes, More Not Flashes” ad features women experiencing common moderate to severe hot flash and night sweat moments that impact their daily lives.
In May 2023, the menopause drug received FDA approval for treating moderate to severe symptoms. Astellas said in Thursday’s announcement that the late-stage results “will support health technology assessment and reimbursement dossiers throughout Europe.”
The withdrawal came days after Astellas Pharma’s prostate cancer drug was spared from the first list of drugs that will be subject to Medicare price negotiations.
Novartis on Friday filed a lawsuit against the Department of Health and Human Services, joining a growing list of industry heavy-hitters seeking to block the Inflation Reduction Act’s Drug Price Negotiation Program.
The company scored a regulatory win for its geographic atrophy eye injection Izervay, just three months after the New Jersey biotech was bought by Astellas Pharma for $5.9 billion.
Under a new collaborative research agreement, Astellas Pharma is turning to an interesting choice of partner to develop a novel antibody-drug conjugate platform for oncology therapeutics. Tuesday, the Tokyo-based biopharma announced a collaboration with tech giant Sony Corporation.
Veozah, an oral once-daily medication, is the first FDA-approved NK3 receptor antagonist for hot flashes, a common symptom of menopause that can affect health and quality of life.
The FDA has approved the combination regimen of Merck’s Keytruda (pembrolizumab) and Seagen and Astellas’ Padcev (enfortumab vedotin-ejfv) for the first-line treatment of locally advanced or metastatic urothelial carcinoma, the companies announced Monday.
Pfizer and Astellas announced positive topline Phase III results Thursday for Xtandi plus leuprolide in non-metastatic castration-sensitive prostate cancer.
